Abstract
Parkinson's disease (PD) is one of the most common neurodegenerative diseases in the elderly. In recent years increasing evidence supports the pharmaceutical potential of curcumin, a polyphenolic compound in the spice turmeric, against PD. Here we briefly summarize the pharmacological activities of curcumin in vitro and in animal models of PD, including counteracting oxidative stress and inflammation, preventing α-synuclein aggregation and fibrillation, and inhibiting monoamine oxidase B, which endow curcumin with multiple pharmaceutical activities against PD and encourage further studies to investigate its clinical effects.
Keywords: Parkinson's disease, curcumin, antioxidant, anti-inflammation, anti-aggregation.
CNS & Neurological Disorders - Drug Targets
Title:The Multiple Pharmaceutical Potential of Curcumin in Parkinson's Disease
Volume: 13 Issue: 2
Author(s): Hong-Fang Ji and Liang Shen
Affiliation:
Keywords: Parkinson's disease, curcumin, antioxidant, anti-inflammation, anti-aggregation.
Abstract: Parkinson's disease (PD) is one of the most common neurodegenerative diseases in the elderly. In recent years increasing evidence supports the pharmaceutical potential of curcumin, a polyphenolic compound in the spice turmeric, against PD. Here we briefly summarize the pharmacological activities of curcumin in vitro and in animal models of PD, including counteracting oxidative stress and inflammation, preventing α-synuclein aggregation and fibrillation, and inhibiting monoamine oxidase B, which endow curcumin with multiple pharmaceutical activities against PD and encourage further studies to investigate its clinical effects.
Export Options
About this article
Cite this article as:
Ji Hong-Fang and Shen Liang, The Multiple Pharmaceutical Potential of Curcumin in Parkinson's Disease, CNS & Neurological Disorders - Drug Targets 2014; 13 (2) . https://dx.doi.org/10.2174/18715273113129990077
DOI https://dx.doi.org/10.2174/18715273113129990077 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Anti-Cancer Activity of Noscapine: A Review
Recent Patents on Anti-Cancer Drug Discovery Editorial (Thematic Issue: New Trends in Pharmaceutical Nanotechnology)
Current Pharmaceutical Design Andrographolide Inhibits Osteopontin Expression and Breast Tumor Growth Through Down Regulation of PI3 Kinase/Akt Signaling Pathway
Current Molecular Medicine Refractory Angina Pectoris: Lessons from the Past and Current Perspectives
Current Pharmaceutical Design Sphere Formation Assay is not an Effective Method for Cancer Stem Cell Derivation and Characterization from the Caco-2 Colorectal Cell Line
Current Stem Cell Research & Therapy Peptide Prodrugs for the Treatment of CNS Disorders: A Perspective for New Drugs
Current Medicinal Chemistry Role of Tyrosine Phosphatase Inhibitors in Cancer Treatment with Emphasis on SH2 Domain-Containing Tyrosine Phosphatases (SHPs)
Anti-Cancer Agents in Medicinal Chemistry Oncolytic Viruses: Programmable Tumour Hunters
Current Gene Therapy Antibody-Drug Conjugate Targets
Current Cancer Drug Targets CXCR4 Inhibitors: Tumor Vasculature and Therapeutic Challenges
Recent Patents on Anti-Cancer Drug Discovery Recent Advances in Luminescent Carbon Dots
Current Analytical Chemistry Recent Development of Anticancer Therapeutics Targeting Akt
Recent Patents on Anti-Cancer Drug Discovery New Perspective on the Dual Functions of Indirubins in Cancer Therapy and Neuroprotection
Anti-Cancer Agents in Medicinal Chemistry Design, Synthesis, Computational and Biological Evaluation of Two New Series of 1, 3- and 1,6-dihydroxy Xanthone Derivatives as Selective COX-2 Inhibitors
Letters in Drug Design & Discovery Anti-Cancer Approach with NK4: Bivalent Action and Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Erlotinib in Glioblastoma - Lost in Translation?
Anti-Cancer Agents in Medicinal Chemistry Intractable Cancers: The Many Faces of Multidrug Resistance and the Many Targets it Presents for Therapeutic Attack
Current Drug Targets 5-HT3 Receptors
Current Pharmaceutical Design Impact of Cellular Senescence in Aging and Cancer
Current Pharmaceutical Design Oncolytic Virus Therapy - Foreword
Current Cancer Drug Targets